Patent · US Active

Antibodies against human IL33R and uses thereof

US9309319B2 · kind B2 · utility

6Cited by

1References

7Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Georg Fertig · Penzberg, DE
Jens Fischer · Penzberg, DE
Guy Georges · Habach, DE
Klaus Kaluza · Bad Heilbrunn, DE
Valeria Lifke · Penzberg, DE
Joerg Moelleken · Penzberg, DE
Sonja Offner · Penzberg, DE
Achal Pashine · Mahwah, US
Stefan Seeber · Penzberg, DE

Key dates

Filing date	Jun 11, 2014
Grant date	Apr 12, 2016
Priority date	—
Expiry date	Oct 7, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.